Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
NCT ID: NCT00240643
Last Updated: 2017-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
640 participants
INTERVENTIONAL
2005-11-30
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Investigate Safety and Tolerability of a Single Dose of AZD6482
NCT00688714
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
NCT02415400
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
NCT00243178
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
NCT01924325
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
NCT00249873
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SB424323
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \</= 60 years old with no heart disease.
* 60 years old with heart disease but no risk factors.
* \>/=60 years old and \</=75 years old with no risk factors and no heart disease.
* Must be able to take aspirin.
Exclusion Criteria
* History of high blood pressure, diabetes or a prior blood clot.
* Liver or kidney disease.
* Need for anti-thrombotic or anti-platelet drugs.
* Need for cardiovascular medicines.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GSK Clinical Disclosure
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Troy, Michigan, United States
GSK Investigational Site
Akron, Ohio, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Camp Hill, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Walla Walla, Washington, United States
GSK Investigational Site
Milwaukee, Wisconsin, United States
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina
GSK Investigational Site
Capital Fefderal, Buenos Aires, Argentina
GSK Investigational Site
Córdoba, Córdoba Province, Argentina
GSK Investigational Site
Córdoba, Córdoba Province, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Moron-Provincia de Buenos Aires, , Argentina
GSK Investigational Site
Antwerp, , Belgium
GSK Investigational Site
Linkebeek, , Belgium
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
São Paulo, São Paulo, Brazil
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Truro, Nova Scotia, Canada
GSK Investigational Site
Burlington, Ontario, Canada
GSK Investigational Site
Grimsby, Ontario, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Newmarket, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Greenfield Park, Quebec, Canada
GSK Investigational Site
Longueuil, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Saint-Lambert, Quebec, Canada
GSK Investigational Site
Trois-Rivières, Quebec, Canada
GSK Investigational Site
Aarhus, , Denmark
GSK Investigational Site
Frederiksberg, , Denmark
GSK Investigational Site
Tallinn, , Estonia
GSK Investigational Site
Tartu, , Estonia
GSK Investigational Site
Créteil, , France
GSK Investigational Site
Mont-de-Marsan, , France
GSK Investigational Site
Toulouse, , France
GSK Investigational Site
Tours, , France
GSK Investigational Site
Künzing, Bavaria, Germany
GSK Investigational Site
Northeim, Lower Saxony, Germany
GSK Investigational Site
Weyhe-Leeste, Lower Saxony, Germany
GSK Investigational Site
Chemnitz, Saxony, Germany
GSK Investigational Site
Ebersbach, Saxony, Germany
GSK Investigational Site
Königsbrück, Saxony, Germany
GSK Investigational Site
Leipzig, Saxony, Germany
GSK Investigational Site
Leipzig, Saxony, Germany
GSK Investigational Site
Leisnig, Saxony, Germany
GSK Investigational Site
Markkleeberg, Saxony, Germany
GSK Investigational Site
Wolmirstedt, Saxony-Anhalt, Germany
GSK Investigational Site
Bad Segeberg, Schleswig-Holstein, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Jena, Thuringia, Germany
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Sopron, , Hungary
GSK Investigational Site
Székesfehérvár, , Hungary
GSK Investigational Site
Szolnok, , Hungary
GSK Investigational Site
Szolnok, , Hungary
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Hyderabad, , India
GSK Investigational Site
Mumbai, , India
GSK Investigational Site
New Delhi, , India
GSK Investigational Site
Catanzaro, Calabria, Italy
GSK Investigational Site
Caserta, Campania, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Città Della Pieve (PG), Umbria, Italy
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
México, , Mexico
GSK Investigational Site
Delft, , Netherlands
GSK Investigational Site
The Hague, , Netherlands
GSK Investigational Site
Utrecht, , Netherlands
GSK Investigational Site
Auckland, , New Zealand
GSK Investigational Site
Christchurch, , New Zealand
GSK Investigational Site
Hamilton, , New Zealand
GSK Investigational Site
Takapuna, Auckland, , New Zealand
GSK Investigational Site
Elverum, , Norway
GSK Investigational Site
Oslo, , Norway
GSK Investigational Site
Skien, , Norway
GSK Investigational Site
Bucharest, , Romania
GSK Investigational Site
Bucharest, , Romania
GSK Investigational Site
Târgu Mureş, , Romania
GSK Investigational Site
Kwangju, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Alicante, , Spain
GSK Investigational Site
Alicante, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Cadiz, , Spain
GSK Investigational Site
Leganés, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Sant Joan d'Alacant, , Spain
GSK Investigational Site
Gothenburg, , Sweden
GSK Investigational Site
Stockholm, , Sweden
GSK Investigational Site
Uppsala, , Sweden
GSK Investigational Site
Taipei, , Taiwan
GSK Investigational Site
Bangkok, , Thailand
GSK Investigational Site
Chiang Mai, , Thailand
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom
GSK Investigational Site
Harrow, Middlesex, United Kingdom
GSK Investigational Site
Northwood, Middlesex, United Kingdom
GSK Investigational Site
Birmingham, West Midlands, United Kingdom
GSK Investigational Site
Antrim, , United Kingdom
GSK Investigational Site
Dundee, , United Kingdom
GSK Investigational Site
Manchester, , United Kingdom
GSK Investigational Site
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
101724
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.